A synthesis strategy for the production of a key synthetic intermediate of gulmirecin A was described. The key reaction in the preparation of the 12-membered macrolactone is the Ni(0)-mediated reductive cyclization reaction of ynal using an N-heterocyclic carbene ligand and silane reductant. In addition, the α-selective glycosylation reaction of the macrolactone was performed to demonstrate the synthesis of gulmirecin and disciformycin precursors.S ince the discovery of antibiotics and vaccines, the number of deaths due to infectious diseases has drastically decreased. However, the frequent prescription and unregulated usage of antibiotics against infectious diseases have permitted drug-resistant bacterial pathogens to spread rapidly. 1 According to the antibiotic resistance threats reported by the U.S. Centers for Disease Control and Prevention in 2019, more than 2.8 million antibiotic-resistant infections occur in the U.S. each year, causing 35,000 deaths. 2 Hence, the development of new antibacterial drugs with novel mechanisms of action is urgently needed to avoid cross-resistance with approved drugs.In 2014, gulmirecin A (1) and B (2) were isolated from Pyxidicoccus fallax HKI 727 as potential antimicrobial agents against Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococci (VRE) (Figure 1). 3 In the same year, disciformycin A (3) and B (4) were isolated from Pyxidicoccus fallax AndGT8 for similar use as potential antimicrobial agents. 4